Everglades Biopharma

Everglades Biopharma is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company's lead asset, EB-001, is a humanized SIRPα-Fc fusion protein that targets the CD47/SIRPα signaling pathway to enhance the immune system's ability to eliminate cancer cells. Licensed from ImmuneOnco Biopharmaceuticals, EB-001 is designed to avoid the hematological toxicities, such as anemia, often associated with other CD47-targeting agents. The company is currently advancing EB-001 through Phase 1/2 clinical trials for the treatment of various hematologic malignancies and solid tumors in North America. Everglades Biopharma is backed by Panacea Venture and operates with a lean, asset-centric model to accelerate clinical development.